Cargando…

Glucose tolerance and insulin responsiveness in Gitelman syndrome patients

OBJECTIVE: Impaired glucose metabolism and insulin sensitivity have been reported in patients with Gitelman syndrome (GS), but insulin secretion and the related mechanisms are not well understood. DESIGN AND METHODS: The serum glucose levels, insulin secretion and insulin sensitivity were evaluated...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Tao, Jiang, Lanping, Chen, Chen, Peng, Xiaoyan, Nie, Min, Li, Xuemei, Xing, Xiaoping, Li, Xuewang, Chen, Limeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5632718/
https://www.ncbi.nlm.nih.gov/pubmed/28432081
http://dx.doi.org/10.1530/EC-17-0014
_version_ 1783269751696392192
author Yuan, Tao
Jiang, Lanping
Chen, Chen
Peng, Xiaoyan
Nie, Min
Li, Xuemei
Xing, Xiaoping
Li, Xuewang
Chen, Limeng
author_facet Yuan, Tao
Jiang, Lanping
Chen, Chen
Peng, Xiaoyan
Nie, Min
Li, Xuemei
Xing, Xiaoping
Li, Xuewang
Chen, Limeng
author_sort Yuan, Tao
collection PubMed
description OBJECTIVE: Impaired glucose metabolism and insulin sensitivity have been reported in patients with Gitelman syndrome (GS), but insulin secretion and the related mechanisms are not well understood. DESIGN AND METHODS: The serum glucose levels, insulin secretion and insulin sensitivity were evaluated in patients with GS (n = 28), patients with type 2 diabetes mellitus (DM) and healthy individuals (n = 20 in both groups) using an oral glucose tolerance test. Serum and urine sodium, potassium and creatinine levels were measured at 0, 30, 60, 120 and 180 min after an oral glucose load was administered. RESULTS: The areas under the serum glucose curves were higher in the GS patients than those in the healthy controls (17.4 ± 5.1 mmol·h/L vs 14.5 ± 2.8 mmol·h/L, P = 0.02) but lower than those in the DM patients (24.8 ± 5.3 mmol·h/L, P < 0.001). The areas under the serum insulin curves and the insulin secretion indexes in GS patients were higher than those in DM patients and lower than those in healthy subjects. The insulin secretion-sensitivity index of GS patients was between that of healthy subjects and DM patients, but the insulin sensitivity indices were not different among the three groups. After one hour of glucose administration, the serum potassium level significantly decreased from baseline, and the urinary potassium-to-creatinine ratio increased gradually and peaked at 2 h. CONCLUSIONS: Glucose metabolism and insulin secretion were impaired in GS patients, but insulin sensitivity was comparable between GS patients and patients with type 2 DM. After administration of an oral glucose load, the plasma potassium level decreased in GS patients due to the increased excretion of potassium in the urine.
format Online
Article
Text
id pubmed-5632718
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Bioscientifica Ltd
record_format MEDLINE/PubMed
spelling pubmed-56327182017-10-12 Glucose tolerance and insulin responsiveness in Gitelman syndrome patients Yuan, Tao Jiang, Lanping Chen, Chen Peng, Xiaoyan Nie, Min Li, Xuemei Xing, Xiaoping Li, Xuewang Chen, Limeng Endocr Connect Research OBJECTIVE: Impaired glucose metabolism and insulin sensitivity have been reported in patients with Gitelman syndrome (GS), but insulin secretion and the related mechanisms are not well understood. DESIGN AND METHODS: The serum glucose levels, insulin secretion and insulin sensitivity were evaluated in patients with GS (n = 28), patients with type 2 diabetes mellitus (DM) and healthy individuals (n = 20 in both groups) using an oral glucose tolerance test. Serum and urine sodium, potassium and creatinine levels were measured at 0, 30, 60, 120 and 180 min after an oral glucose load was administered. RESULTS: The areas under the serum glucose curves were higher in the GS patients than those in the healthy controls (17.4 ± 5.1 mmol·h/L vs 14.5 ± 2.8 mmol·h/L, P = 0.02) but lower than those in the DM patients (24.8 ± 5.3 mmol·h/L, P < 0.001). The areas under the serum insulin curves and the insulin secretion indexes in GS patients were higher than those in DM patients and lower than those in healthy subjects. The insulin secretion-sensitivity index of GS patients was between that of healthy subjects and DM patients, but the insulin sensitivity indices were not different among the three groups. After one hour of glucose administration, the serum potassium level significantly decreased from baseline, and the urinary potassium-to-creatinine ratio increased gradually and peaked at 2 h. CONCLUSIONS: Glucose metabolism and insulin secretion were impaired in GS patients, but insulin sensitivity was comparable between GS patients and patients with type 2 DM. After administration of an oral glucose load, the plasma potassium level decreased in GS patients due to the increased excretion of potassium in the urine. Bioscientifica Ltd 2017-04-21 /pmc/articles/PMC5632718/ /pubmed/28432081 http://dx.doi.org/10.1530/EC-17-0014 Text en © 2017 The authors http://creativecommons.org/licenses/by-nc/4.0/ This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Research
Yuan, Tao
Jiang, Lanping
Chen, Chen
Peng, Xiaoyan
Nie, Min
Li, Xuemei
Xing, Xiaoping
Li, Xuewang
Chen, Limeng
Glucose tolerance and insulin responsiveness in Gitelman syndrome patients
title Glucose tolerance and insulin responsiveness in Gitelman syndrome patients
title_full Glucose tolerance and insulin responsiveness in Gitelman syndrome patients
title_fullStr Glucose tolerance and insulin responsiveness in Gitelman syndrome patients
title_full_unstemmed Glucose tolerance and insulin responsiveness in Gitelman syndrome patients
title_short Glucose tolerance and insulin responsiveness in Gitelman syndrome patients
title_sort glucose tolerance and insulin responsiveness in gitelman syndrome patients
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5632718/
https://www.ncbi.nlm.nih.gov/pubmed/28432081
http://dx.doi.org/10.1530/EC-17-0014
work_keys_str_mv AT yuantao glucosetoleranceandinsulinresponsivenessingitelmansyndromepatients
AT jianglanping glucosetoleranceandinsulinresponsivenessingitelmansyndromepatients
AT chenchen glucosetoleranceandinsulinresponsivenessingitelmansyndromepatients
AT pengxiaoyan glucosetoleranceandinsulinresponsivenessingitelmansyndromepatients
AT niemin glucosetoleranceandinsulinresponsivenessingitelmansyndromepatients
AT lixuemei glucosetoleranceandinsulinresponsivenessingitelmansyndromepatients
AT xingxiaoping glucosetoleranceandinsulinresponsivenessingitelmansyndromepatients
AT lixuewang glucosetoleranceandinsulinresponsivenessingitelmansyndromepatients
AT chenlimeng glucosetoleranceandinsulinresponsivenessingitelmansyndromepatients